##  [New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer](/us-en/news/media-releases/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-interest-hrher2-metastatic-breast-cancer-0 "New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer") 

  Dec 08, 2021